| 1 |
33895784 | Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia. | 2021 Nov |
3 |
| 2 |
34505882 | Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. | 2021 Sep 14 |
1 |
| 3 |
34591931 | Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence. | 2021 |
1 |
| 4 |
27777238 | Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. | 2017 Jan 12 |
1 |
| 5 |
27449287 | CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. | 2016 Sep 13 |
1 |
| 6 |
25976292 | A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). | 2015 Oct |
1 |